The U.S. Food and Drug Administration (FDA) has classified a nationwide recall of chlorthalidone blood pressure tablets as a Class II health risk after the medication failed required dissolution tests. The classification, designated on September 17, 2026, applies to a recall initially launched on September 3 that impacts thousands of prescription bottles distributed across the country.
The affected drug is manufactured by Mumbai-based Inventia Healthcare Limited and distributed in the United States by Rising Pharma Holdings, Inc., located in East Brunswick, New Jersey. Under FDA definitions, a Class II recall indicates that using or being exposed to the product may cause temporary or medically reversible health problems, while the probability of severe adverse health consequences remains low.
Specific Product Details Included in the Recall
The latest action targets more than 13,500 bottles of 25 mg chlorthalidone tablets. Consumers and healthcare providers can identify the impacted medication using the following package and lot details:
- Medication: Chlorthalidone Tablets, USP, 25 mg
- Bottle Size: 100-count bottles
- National Drug Code (NDC): 64980-599-01
- Batch Number: RISA24002
- Expiration Date: April 2027
This marks the second recall for this specific product line within a short period. In June, an earlier recall affected 11,460 bottles across lots RISA24001 and RISB24002 due to the exact same issue with failed dissolution standards.
Dissolution Testing Failures
Chlorthalidone is a widely prescribed diuretic, often referred to as a water pill. It helps reduce high blood pressure and manage fluid retention caused by conditions like kidney disease, liver disease, or heart failure. To work effectively, the active ingredients in the pill must dissolve in the digestive system at a specific rate.
When a drug fails dissolution specifications, the tablet may not break down correctly in the body. As a result, the body absorbs less of the medicine, reducing its ability to lower blood pressure effectively. Patients taking the affected pills may experience reduced therapeutic benefit, even if they follow their dosing schedule correctly.
Important Guidance for Patients
Despite the recall, medical organizations caution patients against stopping their blood pressure treatment without speaking to a healthcare professional. The American Heart Association stresses that suddenly discontinuing high blood pressure medication can lead to dangerous spikes in blood pressure, increasing the immediate risk of a stroke or heart attack.
Patients taking chlorthalidone should check their pill bottles for the recalled batch number and contact their doctor or pharmacist to arrange a replacement prescription or get alternative treatment advice before making any changes.
Broader Trends in Generic Drug Quality
Failed dissolution testing has become a frequent cause of drug recalls in the United States. Federal regulatory tracking shows that dissolution failures were the leading reason for pharmaceutical recalls between 2020 and 2023. Regulatory agencies continue to maintain oversight on imported generic medications to ensure foreign manufacturing facilities meet safety and quality standards before products reach pharmacy shelves.
